Brought to you by 
Biovail pays Aventis $409.5mm for Cardizem
07 Dec 2022
Executive Summary
Biovail (drug products utilizing advanced drug delivery technologies) has agreed to pay Aventis Pharmaceuticals $409.5mm for N. American rights to sell its line of Cardizem (diltiazem) hypertension and angina products. It paid Aventis (uf)$239.5mm up front, and will turn over the remaining fees in equal, quarterly payments throughout 2001.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Marketing (Licensing)
- Product Purchase
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Biovail pays Aventis $409.5mm for Cardizem
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice